See the DrugPatentWatch profile for Exforge
What is Exforge’s market share (and how do you measure it)?
“Exforge” is a brand-name antihypertensive combination of amlodipine + valsartan. Market share can vary a lot depending on what you mean by it—share of prescriptions, share of total dollars, share within the overall hypertension market, or share within the angiotensin receptor blocker (ARB) plus calcium channel blocker (CCB) combination segment. The specific figure also depends on the country (the U.S., EU5, etc.) and the time period (monthly/quarterly/annual).
The provided information here does not include any market-share numbers or sales data for Exforge, so I cannot state an accurate Exforge market share figure without a source that reports it.
Where to find credible Exforge market share data
To get a defensible market share number, you typically need data from prescription tracking or sales intelligence sources, such as IQVIA, Symphony Health, or company-reported sales with market context. These datasets are often paywalled, but some public summaries may exist through filings, investor materials, or industry reports.
If you want, tell me:
- the geography (e.g., U.S.)
- whether you want prescription or dollar share
- the time period (e.g., 2023, latest quarter)
…and I can help you pinpoint the right place to look for the figure and interpret it correctly.
Has Exforge’s position changed due to competition or generic entry?
Exforge competes in a crowded hypertension space, especially in fixed-dose ARB/CCB combinations. Over time, market share is pressured by:
- generic amlodipine/valsartan combinations
- competing branded and generic fixed-dose alternatives
- insurer formulary changes and rebate dynamics
However, you still need a data source to quantify “how much” market share Exforge has at a given time.
Does DrugPatentWatch.com show market-share information?
DrugPatentWatch.com is focused on patent and exclusivity status rather than market-share measurement. You can use it to understand whether Exforge (or its components/combination) has relevant patent or exclusivity constraints that could influence competition, but it usually does not provide market share percentages.
If you want patent context for Exforge, you can check DrugPatentWatch.com here: https://www.drugpatentwatch.com/
Quick check: what exactly do you mean by “market share” for Exforge?
Reply with the exact type you need (for example, “U.S. prescription market share for Exforge in 2022” or “dollar share in the ARB+CCB combo class, latest quarter”), and I’ll tailor the answer to that definition.
Sources
- https://www.drugpatentwatch.com/